This discrepancy suggests that serum IL-7 in ovarian cancer patients may originate from other cell types within the tumor microenvironment (TME; e.g., immune cells or stromal cells) or be indirectly produced via systemic inflammatory responses. This evidence concerns the gene IL7 and ovarian carcinoma.